Kash Shaikh Offer Letter and Equity Awards
In connection with Mr. Shaikh’s appointment as the Company’s President and Chief Executive Officer, the Company has entered into an employment offer letter with Mr. Shaikh, dated as of January 30, 2026 (the “Offer Letter”) that sets forth his employment terms. The Offer Letter provides that Mr. Shaikh will receive an annual base salary of $890,000 and be eligible for an annual performance bonus targeted at 125% of his base salary. The payment of any earned annual bonus will be subject to Mr. Shaikh’s continued employment through the bonus payment date and will be pro-rated for the Company’s 2026 fiscal year. Mr. Shaikh will also receive a $2,000,000 sign-on bonus, which is subject to prorated repayment if, prior to the first anniversary of his start date, the Company terminates Mr. Shaikh’s employment for “cause” or he resigns without “good reason” (each as defined in the Offer Letter).
The Offer Letter provides for the grant of equity awards to Mr. Shaikh under the Company’s 2021 Inducement Plan, consisting of (i) 238,188 initial time-based restricted stock units (“RSUs”), (ii) 137,898 supplemental time-based RSUs, (iii) 137,898 performance-based RSUs (“PSUs”) subject to relative total stockholder return (“TSR”) performance goals, and (iv) 238,188 PSUs subject to stock price appreciation performance goals.
The initial and supplemental time-based RSU awards will each vest as to 25% of the RSUs on April 20, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to Mr. Shaikh’s continued service through the applicable vesting date.
The TSR PSU award will vest subject to the achievement of Company TSR goals relative to the Russell 2000 Index over a three-year performance period beginning on the grant date, as established by the Board or its Compensation Committee, and Mr. Shaikh’s continued service through the achievement certification date.
The stock price appreciation PSU award has a four-year performance period beginning on the grant date and will vest upon certification by the Board’s Compensation Committee that the 30-trading-day average closing price of the Company’s common stock (or, in a change in control of the Company, the per-share transaction value) has equaled or exceeded share appreciation targets of 25%, 50%, 75%, and 100% above the 30-trading-day trailing average closing price of the Company’s common stock preceding the grant date, with cumulative vesting at each level of 50%, 100%, 150%, and 200% of the number of PSUs, respectively. No stock price appreciation PSUs will vest before the first regularly scheduled Compensation Committee meeting on or after the second anniversary of the grant date, and vesting is subject to Mr. Shaikh’s continued service through the applicable achievement certification date.
Pursuant to the Offer Letter, if the Company terminates Mr. Shaikh’s employment without “cause” or Mr. Shaikh resigns for “good reason” (each as defined in the Offer Letter), then, subject to Mr. Shaikh’s execution of a release of claims against the Company, he would receive (i) an amount equal to 100% of his annual base salary in substantially equal installments during the following 12 months, (ii) a pro-rated portion of his annual bonus for the year of termination based on actual performance through the termination date, and (iii) payment or reimbursement for up to 12 months of healthcare continuation coverage. If his termination without cause or resignation for good reason occurs within two months before or 12 months after a change in control, then, subject to Mr. Shaikh’s execution of a release of claims against the Company, Mr. Shaikh would, in lieu of the previously-described payments and benefits, receive (i) an amount equal to 200% of his annual base salary plus 100% of his annual bonus for the most recently completed fiscal year, paid in substantially equal installments during the following 12 months, (ii) a pro-rated portion of his annual bonus for the year of termination based on actual performance through the termination date, (iii) payment or reimbursement for up to 24 months of healthcare continuation coverage, and (iv) unless otherwise provided in an applicable award agreement, 100% vesting of all outstanding equity awards.
The foregoing description of the terms of the Offer Letter is qualified in its entirety by reference to the full text of the Offer Letter, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the second quarter of fiscal 2026.
| Item 7.01 |
Regulation FD Disclosure. |
A copy of the Company’s press release announcing the CEO transition is attached hereto as Exhibit 99.1 and is incorporated by reference.